U.S. Markets closed
  • S&P Futures

    4,145.75
    -0.50 (-0.01%)
     
  • Dow Futures

    34,192.00
    +9.00 (+0.03%)
     
  • Nasdaq Futures

    13,336.75
    -9.25 (-0.07%)
     
  • Russell 2000 Futures

    2,203.70
    +0.40 (+0.02%)
     
  • Crude Oil

    65.56
    +0.28 (+0.43%)
     
  • Gold

    1,836.70
    +0.60 (+0.03%)
     
  • Silver

    27.68
    +0.02 (+0.08%)
     
  • EUR/USD

    1.2152
    0.0000 (-0.0000%)
     
  • 10-Yr Bond

    1.6240
    +0.0220 (+1.37%)
     
  • Vix

    21.84
    +2.18 (+11.09%)
     
  • GBP/USD

    1.4142
    -0.0001 (-0.0099%)
     
  • USD/JPY

    108.6900
    +0.0700 (+0.0644%)
     
  • BTC-USD

    57,027.61
    +1,462.41 (+2.63%)
     
  • CMC Crypto 200

    1,534.30
    +1,291.62 (+532.23%)
     
  • FTSE 100

    6,947.99
    -175.69 (-2.47%)
     
  • Nikkei 225

    28,608.59
    0.00 (0.00%)
     

Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day

  • Oops!
    Something went wrong.
    Please try again later.
Arvinas Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW HAVEN, Conn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks: 2021 Oncology Day on Thursday, February 11 at 4:30 p.m. ET.

A live audio webcast of the presentation will be available here and on Arvinas’ website at www.arvinas.com. A replay of the webcast will be archived on Arvinas’ website for 30 days following the presentation.

About Arvinas
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.

Contacts for Arvinas

Investors
Will O’Connor, Stern Investor Relations
ir@arvinas.com

Media
Kirsten Owens, Arvinas Communications
kirsten.owens@arvinas.com